Supplementary Figure 3 from First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

PDF file - 47K, Association of sVEGR2 changes at the end of the first dosing cycle and patient response in the 500mg BID expansion cohort